GUIDELINES

2019 IUSTI-Europe guideline for the management of anogenital warts

R. Gilson,1,2* D. Nugent,1,2 R.N. Werner,3 J. Ballesteros,4 J. Ross5

1Centre for Clinical Research in Infection and Sexual Health, Institute for Global Health, University College London, London, UK
2The Mortimer Market Centre, Central and North West London NHS Foundation Trust, London, UK
3Department of Dermatology, Venereology and Allergy, Division of Evidence-Based Medicine (dEBM), Charité – Universitätmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany
4Centro Sanitario Sandoval, Madrid, Spain
5University Hospital Birmingham NHS Foundation Trust, Birmingham, UK

*Correspondence: R. Gilson. E-mail: r.gilson@ucl.ac.uk

Abstract

This guideline is an update of the 2011 European Guideline for the Management of Anogenital Warts. It is intended to support best practice in the care of patients with anogenital warts by including evidence-based recommendations on diagnosis, treatment, follow-up and advice to patients. It is intended for use by healthcare professionals in sexual healthcare or dermato-venereology clinics in Europe but may be adapted for use in other settings where the management of anogenital warts is undertaken. As a European guideline, recommendations should be adapted according to national circumstances and healthcare systems. Despite the availability of vaccine to prevent HPV types 6 and 11, the cause of >95% anogenital warts, they remain an important and frequent health problem. The previous systematic review of randomized controlled trials for anogenital warts was updated. The changes in the present guideline include the following: Updated background information on the prevalence, natural history and transmission of human papillomavirus (HPV) infection and anogenital warts. Key recommendations for diagnosis and treatment have been graded according to the strength of the recommendation and the quality of supporting evidence. 5-fluorouracil, local interferon and photodynamic therapy have been evaluated and included as potential second-line treatment options. Evidence of the impact of HPV vaccination on the incidence of anogenital warts has been updated.

Received: 28 May 2019; Accepted: 1 April 2020

Conflict of interest

RG, DN, RNW: none. JB: personal fees from GlaxoSmithKline, Medigene, Bial, Novartis, Meda, 3M, Mylan, MSD, IFC (Industrial Farmaceutica Cantabria). JR: personal fees from GSK Pharma, Hologic Diagnostics and Janssen Pharma; ownership of shares in GSK Pharma and Astrazeneca Pharma; author of the UK and European Guidelines on Pelvic Inflammatory Disease; member of the National Institute for Health Research HTA Commissioning Board; NIHR Journals Editor.

Funding source

None.

Introduction and methodology

This guideline is an update of the 2011 European Guideline for the Management of Anogenital Warts. It provides guidance for best practice in the care of patients with anogenital warts including evidence-based recommendations on diagnosis, treatment, follow-up and advice to patients. It is intended for use by healthcare professionals in sexual healthcare or dermato-venereology clinics in Europe but may be adapted for use in other settings where the management of anogenital warts is undertaken. As a European guideline, recommendations should be adapted according to national circumstances and healthcare systems. Care providers are encouraged to use this guideline to develop local treatment algorithms which take account of their healthcare setting, availability of treatments and needs of their patient population.

The treatment recommendations in the 2011 guidelines were based on a systematic review of randomized controlled trials (RCTs) of anogenital wart treatments. We updated the review using the strategy detailed in Table 1 to identify new studies published since the previous guideline. This was performed using MEDLINE and EMBASE (2009–present) on 13 May 2019.

JEADV 2020, 34, 1644–1653

© 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
systematic reviews of anogenital wart treatments were also considered. We evaluated the evidence that supports our recommendations using the grading system (Table 2) proposed by the British HIV Association Guidelines Group.\textsuperscript{1} We also reviewed the anogenital wart treatment guidelines produced by national groups in the United Kingdom, Germany and United States.\textsuperscript{2–4}


### Aetiology and transmission

Anogenital warts are benign proliferative lesions found on the epithelium of any part of the genitalia, anus or perianal area and may also involve the inguinal or pubic regions. They are caused by human papillomavirus (HPV) genotypes 6 and 11 in >95% of cases.\textsuperscript{5} Multiple HPV types may be present in anogenital warts including ‘high risk’ oncogenic genotypes such as 16 and 18,\textsuperscript{15,16} due to coinfection, but there is no evidence that high risk HPV types cause genital warts. Anogenital warts are a significant public health problem with global estimates of incidence of 160–289 cases per 100 000 person years.\textsuperscript{7} Although Europe-wide data are lacking, estimates of annual incidence in several European countries range from 0.13% to 0.16% of the general population.\textsuperscript{8} Transmission rates of HPV between sexual partners are high and transmission may occur in the absence of visible warts.\textsuperscript{9} Anogenital infection with HPV is common, with a global prevalence of any HPV genotype of 11.7% estimated from cervical cytology samples.\textsuperscript{10} In most cases, the infection is asymptomatic and visible genital lesions develop only in a minority of those infected. However, longitudinal studies have recorded warts developing in 14.6–64.2% of those infected with HPV 6 or 11.\textsuperscript{11–13} The incubation period between incident genital HPV infection and the appearance of warts is highly variable but has been found to be shorter in women (median 2.9 months) than men (median 11.0 months).\textsuperscript{11–12}

### Clinical features

#### Symptoms

Most patients notice only the presence of warts, which are otherwise asymptomatic. However, symptoms can include itching, bleeding or dyspareunia.

---

**Table 1** Search strategy

<table>
<thead>
<tr>
<th>Population (Combine with OR search)</th>
<th>Keywords:</th>
</tr>
</thead>
<tbody>
<tr>
<td>genital wart*</td>
<td>podophyllum, podoflox, podophyllotoxin</td>
</tr>
<tr>
<td>anogenital wart*</td>
<td>podophyllotoxin, podophyllotoxin</td>
</tr>
<tr>
<td>anogenital-wart*</td>
<td>podophyllotoxin, podophyllotoxin</td>
</tr>
<tr>
<td>anal wart*</td>
<td>podophyllotoxin, podophyllotoxin</td>
</tr>
<tr>
<td>condyloma*</td>
<td>podophyllotoxin, podophyllotoxin</td>
</tr>
<tr>
<td>venereal wart</td>
<td>podophyllotoxin, podophyllotoxin</td>
</tr>
<tr>
<td>Plus appropriate mapped/MeSH headings</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Intervention (Combine with OR search)</th>
<th>Keywords:</th>
</tr>
</thead>
<tbody>
<tr>
<td>podophyllum, podoflox, podophyllotoxin</td>
<td></td>
</tr>
<tr>
<td>podophyllotoxin</td>
<td></td>
</tr>
<tr>
<td>cryotherapy</td>
<td></td>
</tr>
<tr>
<td>liquid nitrogen</td>
<td></td>
</tr>
<tr>
<td>imiquimod</td>
<td></td>
</tr>
<tr>
<td>TCA</td>
<td></td>
</tr>
<tr>
<td>trichloroacetic acid</td>
<td></td>
</tr>
<tr>
<td>BCA</td>
<td></td>
</tr>
<tr>
<td>bichloroacetic acid</td>
<td></td>
</tr>
<tr>
<td>curettage</td>
<td></td>
</tr>
<tr>
<td>excision</td>
<td></td>
</tr>
<tr>
<td>laser</td>
<td></td>
</tr>
<tr>
<td>electrocautery</td>
<td></td>
</tr>
<tr>
<td>hycrcation</td>
<td></td>
</tr>
<tr>
<td>ablai*</td>
<td></td>
</tr>
<tr>
<td>diathermy</td>
<td></td>
</tr>
<tr>
<td>5-fluorouracil</td>
<td></td>
</tr>
<tr>
<td>polyphenon</td>
<td></td>
</tr>
<tr>
<td>photodynamic</td>
<td></td>
</tr>
<tr>
<td>tretin* (to capture acitretin, tretinoin, isotretinoin)</td>
<td></td>
</tr>
<tr>
<td>Retinoids</td>
<td></td>
</tr>
<tr>
<td>Plus appropriate mapped/MeSH headings</td>
<td></td>
</tr>
</tbody>
</table>

**Table 2** Grading of recommendations and the quality of evidence

<table>
<thead>
<tr>
<th>Grade</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>A strong recommendation to do (or not do) something, where benefits clearly outweigh risks (or vice versa) for most, if not all, patients. Most clinicians and patients would want to follow a strong recommendation unless there is a clear rationale for an alternative approach</td>
</tr>
<tr>
<td>2</td>
<td>A weaker or conditional recommendation, where the risks and benefits are more closely balanced or are more uncertain. Alternative approaches or strategies may be reasonable depending on the individual patient’s circumstances, preferences and values</td>
</tr>
</tbody>
</table>

| Quality of evidence | |
|---------------------| |
| A                   | High-quality evidence that comes from consistent results from well-performed randomized controlled trials (RCTs), or overwhelming evidence from another source (such as well-executed observational studies with consistent strong effects and exclusion of all potential sources of bias). Grade A implies confidence that the true effect lies close to the estimate of the effect |
| B                   | Moderate-quality evidence from randomized trials that suffers from serious flaws in conduct, inconsistency, indirectness, imprecise estimates, reporting bias, or some combination of these limitations, or from other study designs with specific strengths such as observational studies with consistent effects and exclusion of the majority of the potential sources of bias |
| C                   | Low-quality evidence from controlled trials with several serious limitations, or observational studies with limited evidence on effects and exclusion of most potential sources of bias |
| D                   | Evidence based only on case studies, expert judgement or observational studies with inconsistent effects and a potential for substantial bias, such that there can be little confidence in the effect estimate |
Physical signs

Typical warts appear as superficial papular lesions of 1–5 mm diameter. They may be flat or pedunculated, solitary or multiple. Multiple warts may form larger plaques, particularly in the immunosuppressed or if left untreated. Warts usually match the skin tone but may be more heavily pigmented. They may occur on any area of anogenital skin but commonly affect sites traumatized during sexual intercourse, such as the preputial cavity in men and posterior introitus in women. Anal canal warts are more common in men who have sex with men (MSM) reporting condomless anal intercourse or other sexual practices involving anal penetration. Perianal warts, however, are common in both sexes and can occur in the absence of a history of anal intercourse. A rare variant of HPV 6/11 is characterized by reddish-brown lesions associated with oncogenic HPV types and is part of the clinical spectrum of anogenital intra-epithelial neoplasia. This is a form of verrucous carcinoma which causes local infiltration into underlying dermal structures. The mainstay of management is surgical resection with or without adjuvant chemoradiotherapy, topical retinoids or imiquimod. Specialist referral is warranted. Bowenoid papulosis is a condition characterized by reddish-brown lesions associated with oncogenic HPV types and is part of the clinical spectrum of anogenital intra-epithelial neoplasia. A rare variant of HPV 6/11 disease is the giant condyloma or Buschke–Lowenstein tumour. This is a form of verrucous carcinoma which causes local infiltration into underlying dermal structures. The mainstay of management is surgical resection with or without adjuvant chemoradiotherapy, topical retinoids or imiquimod. Specialist surgical and oncological involvement is required in these cases.

Complications

Psychosexual impact

The negative impact of genital warts on sexual activity and health related quality of life outcomes is well recognized. The condition may cause anxiety, guilt, anger and loss of self-esteem, and lead to concerns regarding future fertility and cancer risk.

Precancer and cancer

Anogenital warts are by definition benign lesions which pose no risk of neoplastic change. However, both premalignant (vulval, anal and penile intra-epithelial neoplasia, i.e. VIN, AIN, and PIN) or malignant lesions can coexist or develop within wart lesions or, rarely, be misdiagnosed as warts. Clinical suspicion of neoplastic change should be aroused by bleeding or an atypical appearance including ulceration or palpable dermal infiltration. In such cases, urgent biopsy or specialist referral is warranted. Bowenoid papulosis is a condition characterized by reddish-brown lesions associated with oncogenic HPV types and is part of the clinical spectrum of anogenital intra-epithelial neoplasia. A rare variant of HPV 6/11 disease is the giant condyloma or Buschke–Lowenstein tumour. This is a form of verrucous carcinoma which causes local infiltration into underlying dermal structures. The mainstay of management is surgical resection with or without adjuvant chemoradiotherapy, topical retinoids or imiquimod. Specialist surgical and oncological involvement is required in these cases.

Diagnosis

- A good light source is recommended for examination (1D).
- Magnification with a lens or colposcope may be useful for small lesions (2D).
- Examination should include inspection of the urethral meatus (1D).
- In female patients presenting with anogenital warts, vaginal or cervical warts are present in an estimated 15% and 6% of individuals respectively. Speculum examination should be offered at initial assessment if cervical or vaginal lesions are suspected, such as when lesions are found at the introitus or when the patient reports being aware of possible internal lesions (1D).
- Perianal inspection should be offered for both sexes at initial assessment or if there are symptoms (e.g. lesions or anal irritation are reported) (1D); digital rectal examination and proctoscopy should be offered if anal canal warts are suspected (e.g. external lesions extending into the anal canal; anal bleeding or discharge) (1D).
- Biopsy is not necessary for typical anogenital warts but is recommended if there is diagnostic uncertainty or suspicion of precancer or cancer (1D).
- The differential diagnosis of genital warts includes molluscum contagiosum and seborrhoeic keratoses as well as normal variants such as penile papules and Fordyce spots.
- Human papillomavirus detection or typing does not influence management and is not recommended.
- Some practitioners use the acetic acid test to diagnose subclinical HPV lesions; its place in diagnosis and management is uncertain.

Management

Information, explanation and advice for the patient

Patients should be given a detailed explanation of their condition, including advice about onward transmission. This should be reinforced by offering them clear and accurate written information. (2D) A patient information leaflet has been produced by IUSTI. (https://iusti.org/wp-content/uploads/2019/11/GenitalWarts2019.pdf).

Treatments

Of the options available currently, only surgical treatment has a primary clearance rate approaching 100%. Recurrences occur after all therapies. Recurrence rates, including new lesions at previously treated or new sites, are often 20–30%, and increase with longer duration of follow-up. All topical treatments are associated with local skin reactions including itching, burning, erosions and pain.

Recommended treatments suitable for self-application

Podophyllotoxin 0.5% solution (1A) and 0.15% cream (2A). Podophyllotoxin is self-applied to lesions twice daily for 3 days, followed by four rest days, for up to 4 or 5 weeks (according to the product licence). Common reactions include transient tenderness, erythema and erosions. Podophyllotoxin is contraindicated during pregnancy, and women of childbearing age must be advised to use an effective method of contraception or abstain from vaginal intercourse during therapy. The use of podophyllotoxin to treat perianal warts is outside the product licence for either preparation, but is well-established in clinical practice. Clinical experience suggests that for ease of application the cream formulation is preferable for
vulval and perianal warts, therefore we suggest the use of podophyllotoxin cream for warts at these sites. A mirror and digital palpation can facilitate the application procedure.

Clearance rates of 36–83% for podophyllotoxin solution27–35 and 43–70% for podophyllotoxin cream28,33,34 have been reported. A recent systematic review and meta-analysis confirmed the effectiveness of podophyllotoxin 0.5% solution relative to placebo (RR: 19.86, 95% CI: 3.88–101.65).36 They found the 0.5% solution to be superior to the 0.15% cream (RR: 1.26, 95% CI: 1.07–1.48) although the individual trials found them to be equivalent. However, neither the meta-analysis nor the included studies were stratified by the site of the warts. One study35 compared podophyllotoxin solution against imiquimod 5% cream and found no difference when treatment with podophyllotoxin was extended for up to 16 weeks.37 Recurrence rates of 6–100% have been reported with podophyllotoxin 8–21 weeks after clearance.27–30,32–34

**Imiquimod cream 5% (1A).** Imiquimod cream is supplied as single use sachets. It is applied directly to the warts three times weekly prior to normal sleeping hours and washed off with soap and water between 6 and 10 h later. Treatment should continue until wart clearance, or for a maximum of 16 weeks. Local inflammatory reactions at the treatment site are common and may precede a treatment response. More severe reactions can be managed by interrupting treatment or by reducing the frequency of application. Severe reactions are uncommon but necessitate discontinuation of therapy.

In clinical studies, wart clearance has been reported in 35–75% of patients with treatment courses up to 16 weeks.35,38–44 The reported clearance rates are higher in women than in men, and women have a shorter median time to clearance than men. A recent Cochrane review of published RCTs found imiquimod to be superior to placebo in achieving complete clearance of warts (RR: 4.03, 95% CI: 2.03–7.99).45 However, the reviewers judged all trials to be at high risk of bias and the review process was limited by heterogeneity of outcomes.

A systematic review assessing the optimum frequency of dosing has been published.46 Daily dosing did not improve wart clearance when compared to three times weekly but did lead to a greater likelihood of treatment interruption due to local adverse reactions in women and uncircumcised men.

Two RCTs have evaluated lower concentrations of imiquimod cream (2.5% and 3.75%) applied daily for up to 8 weeks. Clearance rates were low for men (14.3% and 18.6%) and women (28.3% and 36.6%) for the 2.5% and 3.75% strength respectively.47,48 No RCT has directly compared either lower strength preparation with imiquimod 5%. Imiquimod 3.75% is available in Europe for the treatment of actinic keratoses but it is not licensed for the treatment of warts.

Relatively low recurrence rates (6–26%) after successful clearance have been reported38–40,42,44, but one randomized controlled trial found no difference in recurrence compared to podophyllotoxin.37

Animal studies with imiquimod have not revealed any teratogenic effects in rats or rabbits. Three case series of imiquimod use in pregnant women have been published49–51 and no adverse pregnancy outcomes or fetal abnormalities have been reported. Nevertheless, more data is needed before imiquimod cream can be recommended during pregnancy.

**Sinecatechins (1A).** Sinecatechins are derived from green tea leaves of the *Camellia sinensis* species containing the active ingredient epigallocatechin gallate (EGCG; Polyphenon E®, Mitsubishi Norin Company Ltd, Tokyo, Japan). The mechanism of action is uncertain but various immunomodulatory and antiproliferative properties have been proposed.52,53 EGCG is formulated as a 10% ointment which is marketed in most European countries as Veregen® (Aresus Pharma, Strausberg, Germany) and in the UK as Catephen® (Kora Healthcare, Swords, Ireland). A 15% ointment preparation is only available in the US. The ointment is applied three times daily until complete clearance, or for up to 16 weeks. It cannot be used for internal warts or in pregnancy.

Three double-blind placebo-controlled RCTs have evaluated the 15% ointment54–56 of which two also evaluated the 10% ointment. The study by Gross *et al*.54 also assessed the efficacy of a 10% cream preparation for which wart clearance was not statistically greater than placebo. The trials found no difference in efficacy between the 10% and 15% ointment preparations. A meta-analysis of the three studies37 concluded that both ointment preparations were efficacious relative to placebo. The reported clearance rates of 47–59% are similar to those observed with imiquimod. However, no head-to-head RCTs have been performed and comparison with other treatment trials is limited by heterogeneity of the study populations, as evidenced by the unusually high rates of spontaneous wart clearance in the sinecatechins trials.

Local reactions (most commonly itching and erythema) appear from week 2 of treatment and subside from week 4 onwards, are mostly of mild or moderate intensity and appear to be associated with a clinical response.57 In those who clear warts, low recurrence rates (7–11%) were observed over 12 weeks of follow-up.54–56 There was an unusually high rate of spontaneous clearance in the placebo groups of all 3 studies.

There is a need for trials comparing sinecatechins with other treatments. Whether the dosing schedule is a barrier to patient adherence also needs to be assessed.

**Recommended clinic-based treatments**

**Cryotherapy (1A).** Cryotherapy can be delivered by ‘open’ or ‘closed’ systems. Open application of liquid nitrogen is usually delivered by a spray gun.
device to achieve freezing of the lesion and a margin of healthy skin for a duration of about 20 s. Closed cryoprobe systems utilize circulation of nitrous oxide or carbon dioxide, the probe gently pressed against the lesion moistened with saline or lubricating gel and freezing maintained until a ‘halo’ occurs a few millimetres around the lesion. Up to three freeze-thaw cycles may be applied to each lesion at each session, as tolerated by the patient. There is no standardized application technique and significant inter-operator differences exist. Cryotherapy is usually performed at weekly intervals until wart clearance, although no studies have systematically evaluated different treatment intervals.

Cryotherapy has the advantage of being simple to deliver if the equipment is available, inexpensive and safe in pregnancy. However, the likely need for repeated clinic visits, with the associated healthcare costs, is a disadvantage. Clinical studies report clearance rates of 44–87%58–66 and recurrence rates of 12–42% at 1–3 months and up to 59% at 12 months after clearance.62

Several recent studies have compared wart clearance rates with cryotherapy against other treatments including trichloracetic acid (TCA),66 imiquimod,62 CO2 laser64 and potassium hydroxide.65 Only CO2 laser resulted in superior wart clearance compared to cryotherapy. A recent meta-analysis of studies comparing cryotherapy to other treatments found it to be slightly less efficacious than electrosurgery (pooled RR: 0.80; 95% CI: 0.65–0.99) but not different from TCA, podophyllin or imiquimod.67 There was no comparison with podophyllotoxin included.

Trichloracetic acid 80–90% solution (1A). Trichloracetic acid is a corrosive agent. It is applied sparingly by a healthcare professional directly onto the wart surface with either a wooden or cotton tipped applicator. It is usually applied weekly. It is most suitable for small acuminate or papular warts but less easy to use on keratinized and large lesions. Excess application may cause scarring therefore protection of surrounding skin with petroleum jelly is advised. A neutralizing agent (e.g. 5% sodium bicarbonate) should be readily available in case of spills. When used optimally, a shallow ulcer forms that heals without scarring. Any eschar can be removed with a curette.76,77 Clearance rates of 56–94%58,61,66 and a recurrence rate of 36%58 have been reported. TCA can be used safely during pregnancy.

Surgical treatment. A variety of surgical techniques are in use, including excision, electrosurgery, electrocautery and laser therapy. Surgery may be used as a primary therapy, and the majority of patients can be treated under local rather than general anaesthesia (e.g. 1–2% lidocaine for sub-cutaneous infiltration). The addition of adrenaline reduces bleeding but its use in the penis and in the clitoris region is controversial owing to the potential risk of necrosis.68–70 Its safety has not been established and clinics therefore may choose not to stock the combined preparations to prevent inadvertent use. When performed carefully, simple surgical approaches give highly satisfactory cosmetic results.

Electrosurgery, electrocautery and laser surgery should be performed with the use of surgical masks by the treatment team, and the use of an extractor fan due to the potential presence of infectious HPV particles in the smoke plume generated by these techniques. (1B).71,72

Excision (1A)—Excision under local anaesthetic using scissors, scalpel or curettage is an option when small numbers of lesions are present and for exophytic or pedunculated warts. With the use of diathermy to control bleeding, suturing may not be required. Clearance rates of 89–100% have been reported for scissor excision, with recurrence rates of 19–29%.73–75 Large lesions, anal canal warts and lesions in children may require excision under general anaesthesia and should be referred to an appropriate surgical specialist.

Electrosurgery and electrocautery (1A)—Modern electrosurgical units utilize alternating current to produce different types of waveforms resulting in blends of cutting and coagulation. There are two main approaches:

- Electrocautery (also known as electrofulguration): the passage of a direct or alternating electric current through a resistant electrode tip which generates heat, the application of which leads to immediate tissue destruction. Any eschar can be removed with a curette.
- Electrocautery (including hyfrecation): involves passing a high frequency alternating electrical current directly through an electrode tip. Direct contact of the tip with the lesion causes cutting and coagulation. Electrodesiccation is achieved by maintaining an air gap (1–3 mm) between the electrode tip and the lesion, leading to heating and carbonization of the tissue. As with electrocautery, any eschar can be removed with a curette.76,77

Clearance rates of 94–100% and recurrence rates of 22% have been reported.59,78

Laser surgery (1A)—Laser surgery uses a concentrated beam of infrared, or near infrared, light energy to heat and cauterize the affected area, and allows very high power densities to be delivered to small tissue volumes. The carbon dioxide (CO2) laser and the neodymium–yttrium aluminium garnet (Nd-YAG) laser are in widespread use.79 Clearance rates of close to 100% are usual although recurrence rates of 17–19% at 12 weeks and 66% at 12 months are comparable to other treatment modalities.64,80–82

Therapies for which evidence is limited. Therapies for which there is limited evidence are not generally recommended but may still be considered in cases unresponsive to standard therapies.

5-fluorouracil (2A). 5-fluorouracil (5FU) is an anti-metabolite which blocks DNA synthesis. It is available as a 5% cream which
is used to treat neoplastic and preneoplastic skin conditions including Bowen’s disease and superficial basal cell carcinoma. A Cochrane review concluded that it is superior to placebo in achieving wart clearance but the authors state that the evidence provided by the current studies is weak.83 It cannot be recommended for first-line use, but may be considered when other treatments have failed.

**Intralesional/topical interferon (2A).** There is no evidence for the use of systemic interferon for anogenital warts84,85; however, studies of locally administered interferon, mostly using interferon alpha, have yielded some positive results.86–88 A meta-analysis of studies employing topical or injected intralesional interferon also found that they deliver superior clearance over placebo. We suggest that these treatments may be considered for refractory cases.85

**Combination therapies (2B).** Treatments have often been used in combination.61 There is some theoretical rationale; for example, initial use of an ablative therapy may enhance local penetration of subsequent topical treatment, particularly for keratinized warts. Nonetheless, there is a lack of clinical trial evidence. In one placebo-controlled study, adjuvant podophyllotoxin cream following cryotherapy did not improve wart clearance at 4, 12 or 24 weeks post-treatment initiation.63 Further evaluation of such treatment approaches is warranted, given the limited efficacy of most treatments and the frequency of recurrence.

**Photodynamic therapy (2A).** Photodynamic therapy (PDT) employs topical 5-aminolevulinic acid (ALA) as photosensitizer, followed by irradiation with red light to induce cell death or immunomodulation through generation of reactive oxygen species. Its uses include the treatment of actinic keratoses, basal cell carcinomas and Bowen’s disease.89 Studies of its use as adjuvant82,90 and stand-alone treatment80,81 in genital warts show some efficacy but there is not yet sufficient data to recommend this approach for first-line treatment.

**Therapies not generally recommended Podophyllin.** Podophyllin 20–25%, a non-standardized resin extract from the *Podophyllum* plant, is inexpensive to produce but is less effective than podophyllotoxin. Podophyllin preparations contain a variety of compounds some of which may be mutagenic91 and severe systemic toxicity after topical use has been described including death, intrauterine death, teratogenicity and neurological complications.92

**Treatment algorithms** There is no single optimum treatment for anogenital warts. All modalities of treatment have advantages and limitations, and all are associated with a substantial risk of wart recurrence. Evaluation of the evidence is limited by the heterogeneity of study designs and reporting outcomes and a lack of head-to-head comparisons between treatments. Patient-centred outcomes, in particular satisfaction with treatment, have been largely overlooked. Future studies should address these limitations.

Clinicians who treat anogenital warts should have access to a range of home and clinic-based therapies. Choice of therapy depends on the site, morphology and extent of warts and patient preference and requires discussion between the physician and the patient. Warts may regress spontaneously so that no treatment, or deferring treatment is a management option. Patients need to be advised, however, that lesions may get larger, or spread, and there may be an impact on the likelihood of transmission.

Availability and cost may also dictate choice of treatment, and cost effectiveness will vary between healthcare systems. An extensive systematic review and meta-analysis proposed a strategy of initial treatment with podophyllotoxin solution 0.5% followed by CO₂ laser therapy second line as the most cost effective from a UK perspective.77 Care providers are encouraged to develop local treatment algorithms which address the needs of their patient population and are deliverable with the resources available to the service. (1B) Implementation of such algorithms has been shown to improve outcomes.93

**Treatment in special situations** Vaginal, cervical, intra-meatal, intra-anal warts (2C). Vaginal warts can be treated with either cryotherapy, TCA or any surgical treatment modality. Cervical warts require gynaecological referral and, if treatment is required, cryotherapy, TCA or any surgical treatment modality is also acceptable. Intra-meatal warts can be treated surgically (including excision, electrosurgery or laser ablation). Podophyllotoxin, imiquimod or cryotherapy are acceptable alternatives if the base of the lesion is clearly visible. Anal canal warts can be treated with cryotherapy, TCA or any surgical treatment. Imiquimod use is also possible with suitable patient motivation, but is not licensed for use at this site. Surgical referral may be required.

**Treatment in pregnancy** (1D). In pregnancy, warts may enlarge and multiply. Topical treatments should be avoided but ablation using cryotherapy, TCA or any surgical treatment modality is acceptable. The presence of warts rarely impacts on the mode of delivery unless there is obstruction of the birth canal due to very large warts. Liaison with the obstetrician in management is recommended in all cases. Spontaneous regression of genital warts is frequently seen in the puerperium. Delaying treatment until after delivery is common practice.

Juvenile onset recurrent respiratory papillomatosis is a very rare complication of vertically transmitted HPV, occurring in approximately 4/100 000 live births.94 There is no proof that treatment of the mother diminishes this risk, although reduction of viral burden would seem prudent through treatment in cases of very extensive warts.
Treatment in immunocompromized patients (2A). Both HIV infection and other causes of systemic immunosuppression are associated with an increased incidence of warts. Moreover, the response to treatment in HIV-positive subjects is impaired, and recurrences after treatment are more common95,96 although whether this applies to those on effective HIV therapy with a normal CD4 count is not known. A recent systematic review and meta-analysis of treatments in HIV-positive patients found evidence to support imiquimod for the partial clearance of external warts only, highlighting the urgent need for further data in this group.97 Repeated or prolonged treatments may be necessary.

Partner notification
Current partners of patients with anogenital warts should be offered clinical assessment for the presence of warts along with education and advice about HPV infection and screening for other sexually transmitted infections. (2D)

Follow-up (2D)
Evidence is lacking regarding the optimal schedule for follow-up and guidelines differ in their recommendations.3,4 We suggest that local management protocols incorporate medical review of cases at regular intervals, for example, every 4 weeks, until warts have resolved, with switching of treatments if an inadequate response is observed. Patients with immunodeficiency or who are otherwise immunocompromised may remain at increased risk of recurrence of HPV-related disease, even after successful treatment and clearance of wart lesions. Such patients should be counselled on the importance of self-surveillance for new lesions and regular clinical review should be considered on a case-by-case basis.

Prevention, health promotion and vaccination
- Patients with first episode genital warts should be offered sexually transmitted infection screening as per local guidelines. (1D)
- Female patients should be informed about cervical cytology screening as per local or national guidelines. (1D)
- Condoms have been shown to at least partially protect against the acquisition of anogenital warts.98,99 Whether condoms protect against HPV transmission per se is less clear99 but some data suggest that male condom use may protect female partners against HPV acquisition.9,99 The prevalence of HPV DNA has also been shown to be lower in men who consistently use condoms.100 Condom use has been shown to accelerate disease resolution when both partners have type-concordant HPV infection.100,102,103 Therefore, condom use is recommended when either partner has genital warts until resolution of lesions; (1A) but patients should be advised that they offer only partial protection against onward transmission. (2A)
- Cigarette smoking is associated with an increased risk of genital warts in a dose dependent manner even after adjustment for sexual behaviour.104 It is also associated with persistence of anogenital HPV infection.105 Although there is no evidence that smoking cessation improves outcomes of wart treatment, there is a clear individual and public health rationale for advising smoking cessation. (1C)
- Vaccination with Gardasil® (MSD Vaccins, Lyons, France) and Gardasil®9 (MSD Vaccins) both provide durable protection against HPV genotypes 6 and 11, which cause the majority of anogenital warts. A recent trial suggested that there may be a benefit in using vaccine in conjunction with topical imiquimod or podophyllotoxin for the treatment, or prevention of recurrence, of genital warts but this has not been established.37 There is no evidence of benefit in those with HPV infection, but no clinical disease. Vaccination prior to sexual debut will maximize the protective benefits. Countries differ in their HPV vaccination strategies. However, substantial reductions in genital wart incidence in young women and heterosexual men have been observed in Australia following the introduction of Gardasil® (MSD Vaccins) vaccine for schoolgirls.106 Unexpectedly, a reduction in genital wart episodes was also seen in women and heterosexual men aged 15–19 in the UK following introduction of the bivalent vaccine Cervarix® (GlaxoSmithKline Biologicals S.A., Rixensart, Belgium).107

Composition of editorial board

List of contributing organizations
Please see https://iusti.org/regions/europe/guidelines-introduction/.

References


Szeimies RM, Schleyer V, Moll I, Stocker M, Landthaler M, Karrer S. Adjuvant photodynamic therapy does not prevent recurrence of condylomata acuminate after carbon dioxide laser ablation - a phase III,


